This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.This pilot, open label trial aims at evaluating the efficacy of Exenatide as adjunctive therapy in type 1 diabetic patients, recipients of islet allografts that have fasting C-peptide levels of > 0.5 ng/ml but have been unable to maintain normal glucose control without exogenous insulin administration. Specifically, we plan to test the hypothesis that the use of Exenatide (10 mg sc tid) for a 6 month period in patients that have received al least 10,000 IE/kg with 1 or 2 transplants and are at least 6 months after the last transplant would result in improved glycemic control and permit the discontinuation of exogenous insulin therapy while maintaining HbA1c level < 7.0%.
Showing the most recent 10 out of 945 publications
